Sponsors (7)
The bill aims to improve transparency and ensure accurate payment for high-cost outpatient cancer drugs while preventing increases in Medicare spending, but it risks higher patient cost-sharing, payment offsets that could reduce other outpatient reimbursements, and added administrative complexity.
Medicare beneficiaries will have certain high-cost outpatient cancer drugs billed and paid separately, increasing price transparency and making it easier to identify and secure access to these therapies.
The bill requires budget-neutrality for the carve-out, which limits increases in overall Medicare OPD spending and reduces immediate cost pressure on taxpayers and the Medicare program.
Hospitals and health systems treating patients with expensive outpatient cancer drugs can receive more accurate reimbursement for those drugs, reducing financial losses when providing high-cost therapies.
Medicare beneficiaries could face higher out-of-pocket cost-sharing because separate drug payments may increase patient coinsurance tied to the drug price.
The budget-neutrality requirement may force offsets elsewhere in the OPD fee schedule, potentially lowering reimbursements for other outpatient services and reducing resources for ancillary care.
A relatively low carve-out threshold ($350/day in 2026) could capture many treatments, creating substantial additional administrative burden for hospitals and CMS to track, price, and process separate claims.
Based on analysis of 2 sections of legislative text.
Requires separate Medicare OPD payment for certain high-cost cancer drugs/biologics above a per-day cost threshold, paid by ASP (or WAC/claims fallback) beginning in 2026.
Official title: To amend title XVIII of the Social Security Act to ensure equitable payment for, and preserve Medicare beneficiary access to, cancer treatments under the Medicare hospital outpatient prospective payment system.
Introduced March 20, 2026 by Neal Patrick Dunn · Last progress March 20, 2026
Requires Medicare to pay separately for certain high-cost cancer drugs and biologics furnished in outpatient departments beginning in 2026 rather than packaging their cost into the bundled outpatient department (OPD) payment. Drugs that meet a per-day product cost threshold ($350 in 2026, then indexed) are reimbursed using average sales price (ASP) or fallback prices, with budget-neutral adjustments so overall spending under the OPD payment policy does not increase. This change aims to remove expensive cancer drugs from OPD bundled payments so hospitals and providers receive distinct drug reimbursement, affecting Medicare beneficiaries who receive these cancer treatments, hospitals and outpatient facilities, and drug manufacturers whose products meet the threshold.